Equities

Mendus AB (publ)

Mendus AB (publ)

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (SEK)8.19
  • Today's Change0.11 / 1.36%
  • Shares traded20.11k
  • 1 Year change-5.90%
  • Beta1.2686
Data delayed at least 15 minutes, as of Sep 20 2024 17:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of SEK
(except for per share items)
Fiscal data as of Dec 31 2023202320222021
ASSETS
Cash And Short Term Investments12142155
Total Receivables, Net3.303.4420
Total Inventory------
Prepaid expenses641.9210
Other current assets, total------
Total current assets18847185
Property, plant & equipment, net23260.36
Goodwill, net108108108
Intangibles, net424424424
Long term investments------
Note receivable - long term0.620.620.84
Other long term assets11142.11
Total assets756620721
LIABILITIES
Accounts payable8.137.4112
Accrued expenses171611
Notes payable/short-term debt000
Current portion long-term debt/capital leases2.52320.31
Other current liabilities, total1.634.775.15
Total current liabilities295928
Total long term debt21240
Total debt24550.31
Deferred income tax------
Minority interest------
Other liabilities, total0.852337
Total liabilities5110664
SHAREHOLDERS EQUITY
Common stock439.979.97
Additional paid-in capital1,3951,1311,130
Retained earnings (accumulated deficit)(733)(626)(484)
Treasury stock - common------
Unrealized gain (loss)------
Other equity, total------
Total equity705514657
Total liabilities & shareholders' equity756620721
Total common shares outstanding431111
Treasury shares - common primary issue000
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.